Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit

Chiome Bioscience a biotechnology company with its focus on discovery and development of antibody-based therapeutics in the disease area where high unmet medical needs exist, such like oncology, immunology, CNS, and inflammatory. It has several programs in discovery and preclinical stage in these fields. Chiome owns proprietary antibody generating technology named ADLib® System, together with currently available platforms. It was founded in 2005 and is listed on Tokyo stock exchange Mothers (code: 4583), and is located in Tokyo, Japan.

Senju Pharmaceutical Co.,Ltd. develops pharmaceutical products for eye, ear, nose, throat, and skin care. It offers prescription drugs in various categories, such as inflammation, allergy, glaucoma, cataract, infection, surgical aid, and cornea protection. The company also offers over-the-counter products. It serves customers in Asia, North and South America, Europe, and the Middle East. Senju Pharmaceutical Co.,Ltd. was founded in 1947 and is based in Osaka, Japan.

Immune Biosolutions is an innovative biotech company focused on the discovery and engineering of transformational chicken antibodies targeting difficult proteins with a validated, yet unexploited, therapeutic potential.

4 Westmount Square, Suite 160
Montreal, Quebec H3Z 2S6

Business Development:
Human Resources:
General Inquiries:

© Copyright 2018-2021 SemaThera Inc.